A Vancouver-based company has attracted venture capital for its flagship project, a nitric oxide nasal spray shown in clinical studies to treat and prevent Covid-19 infection, including a recent Phase 3 study published in The Lancet Regional Health Southeast Asia. SaNOtize Research & Development Corp. announced recently that it raised an oversubscribed $24 million Series B funding […]